Research firm notes 'top five vaccine industry trends' of 2016

19 December 2016

The vaccine market continued its growth and innovation in 2016, according to a new report, which notes that segment growth, the growing obesity challenge and delivery systems were among the trends noted this year.

Kalorama Information said that Merck & Co (NYSE: MRK), Sanofi Pasteur, a unit of French drug major Sanofi (Euronext: SAN), Pfizer (NYSE: PFE), GlaxoSmithKline (LSE: GSK) and Australia’s CSL Ltd (ASX: CSL) are among the top companies in the market. The healthcare market research publisher has studied vaccine markets for a decade, and this year published its report Vaccines 2016.

Kalorama noted the following important trends in vaccines in 2016:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK